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ABSTRACT
Introduction. This study investigated changes in kidney function over time among a
cohort of patients undergoing pancreas transplantation alone (PTA) from January 2002 to
December 2011.
Patients and Methods. Ten of eighteen PTA patients bearing functioning grafts for at
least 1 year were recruited for the analysis. Primary endpoints were changes in mean serum
creatinine (SCr, mg/L) and mean estimated glomerular filtration rate (eGFR) using the
4-variable Levey-MDRD equation (mL/min/1.73 m2) comparing baseline (pretransplan-
tation) to 6-month, 1-year, 3-year, and 5-year posttransplantation values. Mean follow-up
time was 75.7  20.5 months (range, 46–106.5).
Results. Baseline eGFR was 89.3  27.9 (range, 58–145). eGFR decreased to 75.7 
26.2, 71  20.6, 66.5  14.8, and 62.1  11.2 at 6 months, 1, 3, and 5 years representing
15.2%,20.5%,15.8%, and22.6% percentage decreases respectively (P .05 for all
pairwise comparisons). The Baseline SCr was 8.6  2.3 mg/L (range, 5–13). SCr
progressively increased to 10.1  3, 10.5  3.1, 10.9  3.1, and 11.3  1.7 at 6 months, 1,
3, and 5 years a 17.1%, 22%, 16.6%, and 19.9% increase respectively (P  .05 for all
pairwise comparisons). One of ten, 2/8, and 3/7 patients displayed an eGFR 60 at
transplantation versus 3 and 5 years thereafter, respectively. No patient developed a SCr
 25 mg/L or eGFR 30 or needed dialysis or kidney transplantation. Five of ten patients
had micro-albuminuria or proteinuria before transplantation. Tacrolimus levels were
within recommended therapeutic ranges over time.
Conclusion. Kidney function deteriorated significantly after PTA. Understanding of risk
factors for the development of renal impairment is important to preserve kidney function




fPANCREAS transplantation alone (PTA) enables pa-tients to be insulin-independent with normalized glu-
cose metabolism, thereby halting or reversing early diabetic
nephropathy.1 However, it is a challenging technique with a
high incidence of surgical complications together with an
elevated risk of immunologic responses.2 Additionally the
nephrotoxic effects of life-long immunosuppressive therapy
on native kidney function posttransplantation could coun-
terbalance the late beneficial impacts of glycemic control.3
Thus, compared with other types of pancreas transplanta-
tion, only a small proportion of cases are PTA. Few studies
of the natural history of kidney function have been per-
formed among diabetic populations undergoing beta-cell
replacement by either islet transplantation or PTA. The
understanding of risk factors for the decline in native
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unction and to select appropriate candidates for transplan-
ation. This study sought to examine changes in kidney
unction over time among a cohort of PTA to evaluate
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2830 LE DINH, DeROOVER, COIMBRA ET ALpotential recipient risk factors related to a progressive
decline in kidney function posttransplantation.
PATIENTS AND METHODS
We performed a retrospective study of 18 PTA and 28 simultane-
ous pancreas and kidney (SPK) transplantations performed in 15
and 28 patients, respectively from January 2002 to December 2011.
Ten PTA patients with functioning pancreas grafts for at least 1
year were recruited for the analysis. All patients displayed brittle
insulin-dependent diabetes mellitus (IDDM) with frequent hypo-
glycemic episodes and hypoglycemic unawareness, coma and/or
seizures, and/or inability to function without help. Indications for
PTA included type-1 IDDM (n  9) and de novo diabetes after
hepatic transplantation (n  1). The average follow-up was 75.7 
20.5 months (range, 46–106.5).
Transplant Procedure
In all cases, the pancreas was recovered from a brain-dead donor as
part of a multi-organ procurement. After flushing it was cold-
stored in University of Wisconsin solution. Mean donor age was
29.2  13.6 years (range, 15–56), all of them were male. Mean
onor body mass index (BMI) was 23.7  2.7 kg/m2 (range,
19.4–29.4). Mean cold ischemia and suture times were 478  193
(range, 152– 694) and 31  3.2 minutes (range, 24–35), respec-
ively. A common aortic patch carrying the celiac trunk and the
uperior mesenteric artery (SMA) was present in 8 grafts, whereas
n arterial reconstruction with a donor iliac artery Y graft was
ecessary in 2 cases. Portal vein extension was required for 3 grafts.
Mean recipient ages at the time of transplantation and of IDDM
iagnosis were 36  9.6 (range, 21–55) and 15.7  14.3 years
(range, 3–51), respectively. Mean duration of IDDM was 20.4 
12.1 years (range, 3–40). The male/female ratio was 3/7. Mean
recipient BMI was 25  2.9 kg/m2 (range, 21.4–30.1). Mean HLA
ismatches were 3  1.2 (range, 0–4). The transplantation was a
primary graft (n  8) or a retransplantation (n  2). Transplanta-
tion was performed trans-peritoneally through a midline incision
with the pancreas graft placed fully in a retro-peritoneal location in
the right iliac fosse. To manage exocrine secretions, duodeno-
cystostomy, duodeno-jejunostomy, or duodeno-duodenostomy
were constructed in 2, 5, and 3 cases, respectively. We tended to
perform a duodeno-duodenostomy technique for PTA due to the
advantage to monitor the graft duodenum via upper endoscopy.
The donor portal vein was anastomosed end-to-side to a major
tributary of the recipient superior mesenteric vein (n  6) or
end-to-side to the recipient external iliac vein (n  4). The arterial
nastomosis was usually constructed in end-to-side fashion be-
ween the donor iliac artery Y graft (or the common aortic patch of
eliac trunk and SMA) and the recipient common iliac artery.
Perioperative and Postoperative Management
Induction therapy consisted of either a lymphocyte-depleting agent
(thymoglobulin or rATG) or an anti-CD25 monoclonal antibody
(basixilimab); maintenance therapy combined 3 immunosuppres-
sive drugs-tacrolimus, my7cophenolate mofetil or mycophenolic
acid, and steroids. Tacrolimus was adjusted to achieve whole blood
trough levels of 10–15 ng/mL during the first 3 months posttrans-
plantation, 7–10 ng/mL from month 3 to month 12, and 5–7 ng/mL
thereafter. Steroids (methylprednisone) were progressively tapered
to attain 4 mg/d by 3 months and completely withdrawn from
month 6. Anti-infective prophylaxis comprised Tazocin (piperacil-lin and tazobactam) in association with Diflucan (fluconazole) for
the first 5 days, sulfamethoxazole/trimethoprim for pneumocystis
and urinary tract infection for at least 6–12 months, and valgancy
clovir for cytomegalovirus (CMV) depending on donor and recip-
ient CMV serological status (if D/R: valganciclovir for 3
months; other cases: acyclovir for herpes virus for 3 months).
The pancreas grafts were monitored with serum analyse and
lipase, urinary amylase (if the pancreas exocrine gland was drained
into the bladder), blood glucose, and HbAlc (glycosylated hemo-
globin A1c). Abdominal scan with contrast injection to assess the
graft perfusion was routinely performed at day 5 posttransplan-
tation when there was any suspicion of technical complications.
A protocol duodenal biopsy was applied at 3 and 8 weeks
posttransplantation followed by every 3 months for the first year
and yearly afterward in cases of PTA with duodeno-duodenal
drainage. Otherwise in the presence of any of the following
signs—hyperamylasemia, hyperlipasemia, unexplained hyper-
glycemia, fever, or graft tenderness—suspected pancreas rejec-
tion was treated empirically.
Study Design and Statistical Analysis
Serum creatinine (SCr, mg/L) and eGFR, which was calculated via
the 4-variable Levey-Modification of Diet in Renal Disease
(MDRD) equation (mL/min/1.73 m2) were used to evaluate renal
function. We compared the mean changes in SCr and eGFR from
baseline (pretransplantation) to 6 months, 1 year as well as 3 and 5
years posttransplantation.
Continuous variables were expressed as mean values  standard
deviation (SD), categorical variables were expressed as proportions
or percentage. Intragroup comparisons were performed using
paired Student t tests for continuous parameters. Graft and patient
survival rates estimated using the Kaplan-Meier method were and
compared using the log-rank test. P  .05 was considered to be
statistically significant. All data were analyzed using SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
Eight PTA grafts were excluded from this analysis due to
early graft thrombosis on day 1, day 2, or day 60 posttrans-
plantation (n 3), late graft thrombosis at 7.5 months (n
1), rejection at months 3 and 4 (n  2), and functioning for
ess than 1 year (n  2). In these cases, the drainage
echnique consisted of systemic-vesical (n  1), systemic-
duodenal (n  1), systemic-enteric (n  3), and portal-
duodenal (n  3).
Cohort of 10 PTA Transplants
Baseline SCr level of 8.6  2.3 mg/L (range, 5–13) progres-
sively increased to 10.4  3.5 at 3 months (P  .01), 10.1 
at 6 months (P  .00), 10.5  3.1 at 1 year (P  .03), 10.9
3.1 at 3 years (P  .02), and 11.3  1.7 at 5 years (P 
02). The percentage increase in SCr was 21.5%, 17.1%,
2%, 16.6%, and 19.9% at these times. Baseline eGFR of
9.3 27.9 mL/min (range, 58–145) decreased to 74 26.8
P  .00), 75.7  26.2 (P  .00), 71  20.6 (P .04), 66.5 
14.8 (P  .02), and 62.1  11.2 (P  .01) at 3 and 6 months
as well as 1, 3, and 5 years, respectively. The mean absolute
decrease in eGFR was 15.3, 13.6, 18.3, 12.5, and





NATIVE KIDNEY FUNCTION 2831to 17.1%, 15.2%, 20.5%, 15.8%, and 22.6% re-
pectively.
One of ten patients displayed an eGFR 60 mL/min at
ransplantation, which increased to 3/10 patients at 3
onths and 1 year, 2/8 at 3 years, and 3/7 at 5 years
osttransplantation. No patients developed a SCr 25
mg/L an eGFR30, or needed dialysis or kidney transplan-
tation.
Five of ten patients displayed micro-albuminuria (n  3)
or proteinuria (n  2) before transplantation. Yearly
urinalyses showed diminution or disappearance of a albu-
minuria or proteinuria in 3/5 of them. However, 2 patients
who were negative for proteinuria pretransplantation de-
veloped a moderate degree thereafter. One female patient
presented with nephropathy prior to PTA probably due to
the use of immunosuppressive drugs in the context of 2
previous hepatic transplantations. She became pregnant
twice after PTA: one was a fetal intrauterine death and the
other, a live birth. Excessive weight gain posttransplanta-
tion was observed in 2 patients. The tacrolimus trough
levels were 10.4  1.5 (range, 8.1–13.2) at 3 months, 8.8 
2.6 (range, 4.8–13.5) at 6 months, 10.1  2.5 (range,
6.5–14.2) at 1 year, 6.8  2.1 (range, 4.5–10) at 3 years, and
6.4  1.7 (range, 3.9–8.9) at 5 years. The 7 acute rejection
episodes diagnosed in 5 patients all responded to steroid
bolus treatment. Table 1 presents the glucose metabolic
profile of PTA patients posttransplantation.
Whole Cohort of 18 PTA and 28 SPK Transplantations
The 8 PTA lost grafts were due to arterial thrombosis either
on day 2 postoperatively (n  1) or from 2 to 18 months
posttransplantation (n 4), portal vein thrombosis (n 1),
and rejection (n  2). Transplantectomy was performed in
6 cases. Overall pancreas graft survival rates were 76.6%,
57.4%, 51.1%, and 51.1% at 3 months, 1 year, 3 years, and
5 years, respectively. Three patients who lost their pancreas
grafts underwent retransplantation shortly later. One pa-
tient was to lost follow-up at 69 months posttransplantation,
and another died after a myocardial infarction at month 16.
Overall patient survival rates were 100%, 100%, 93.3%, and
93.3% at the corresponding times. Among 3 grafts whose
pancreas exocrine secretions were drained into the bladder,
conversion to enteric drainage was necessary in 1 subject at
month 8 posttransplantation because of severe symptomatic






- 91.4  15.8
(72-116)
bA1c (%) 8.9  1.2 5.7  0.4
(7.4-11) (4.9-6.2)
C-peptide (pmol/mL) 0.03  0.02 1.2  0.4
(0-0.07) (0.5-1.7)Pretransplant plasma glucose levels fluctuated in a wide range and were not colleday 2 postoperatively; the remaining patient tolerated the
technique without side-effects up to now. Thirteen acute
rejection episodes, which occurred in 10 patients, were
confirmed by either protocol biopsy (n  6 episodes) or
by-cause biopsy (n  7 episodes), leading to graft loss in 2
cases.
The SPK cohort included 7 pancreas grafts lost secondary
to arterial thrombosis (n  2), portal vein thrombosis (n 
1), digestive fistula (n  1), rejection (n  2), or patient
death with a functioning graft (n  1). Transplantectomy
was performed in 4 cases. Overall pancreas graft survival
rates were 85.7%, 82.1%, 82.1%, and 72.7% at 3 months, 1
year, 3 years, and 5 years, respectively (Fig 1). No retrans-
plantation was attempted. Four patients died due to sepsis
(n  2), pulmonary emboli (n  1), or massive digestive
hemorrhage (n 1) caused by a fistula of the pancreas graft
artery into the digestive tube. Overall patient survival rates
were 92.9%, 92.9%, 92.9%, and 88.2% at the corresponding
times (Fig 2). Regarding kidney transplantation, 5 grafts
were lost because of renal artery and vein thrombosis (n 
1), rejection related to noncompliance to immunosuppres-
sive drug therapy (n  1), or death with a functioning graft
(n  3). Overall kidney graft survival rates were 89.3%,
89.3%, 89.3%, and 79.3% at 3 months, 1 year, 3 years, and
5 years, respectively. There was no primary kidney graft
nonfunction; delayed graft function was observed in 1
subject. Among 9 acute kidney rejection episodes, 2 were
diagnosed by protocol biopsy at 3 months posttransplanta-
tion, whereas the others by a for- cause biopsy Two
pancreas rejection episodes were suspected at the time of
kidney rejection, resulting in pancreas graft loss in 1 patient,
who had a history of noncompliance to immunosuppressive
therapy.
DISCUSSION
Our results were consistent with previously publishe obser-
vations, confirming the significant deterioration of native
kidney function after PTA. The decreased eGFR, which
occured precociously in the posttransplantation period,
continuously progressed. Most of the decrease observed in
this study occurred within the first 3 months posttransplan-
tation. The eGFR was reduced by 17.1% at 3 months,
20.5% at 1 year, and 22.6% at 5 years, leading to an
increased number of PTA patients with posttransplantation
eGFR 60 mL/min over time. Fortunately, no patients
lic Profile in PTA
Posttransplant
months 1 year 3 years 5 years
9  16.1 91.2  16.9 93.5  14.9 99  7
0-121) (70-122) (75-119) (85-107)
5  0.6 5.7  0.4 5.7  0.3 5.6  0.3
.1-6.3) (5.1-6.5) (5.2-6.1) (5.2-6.2)
5  0.6 1.2  0.7 1.3  0.5 1.2  0.4






















2832 LE DINH, DeROOVER, COIMBRA ET ALdisplayed an eGFR 30 mL/min or required renal replace-
ment therapy. Gruessner et al reported 2% or 12% of PTA
recipients to develop kidney failure, as defined by the need
for dialysis or kidney transplantation at 1 or 5 years after
transplantation in the tacrolimus era. The corresponding
numbers in the cyclosporine era were 5% and 13%. In total,
15% of PTA patients under a calcineurin inhibitor (CNI)
regimen develop kidney failure at 5 years.4 An impact of
PTA on the decreased kidney function was demonstrated by
both direct measurement of GFR5 and calculation meth-
ods, which have generally shown a good correlation.5,6
Various factors seemed to have been involved in the
impaired renal function post-PTA. Recipient age younger
than 30 years and SCr 15 mg/L at the time of pancreas
transplantation were associated with kidney failure in PTA
recipients using a multivariate analysis.4 An eGFR 60 or
0 mL/min prior to transplantation was also linked to a
reater likelihood of progression to clinically significant
idney disease.6,7 Albuminuria or proteinuria prior to trans-
plantation, which reflect the underlying subclinical diabetic
nephropathy may predispose the native kidney to injury
posttransplantation.6 Polyoma virus arising from the native
kidneys may also contribute to the rapid evolution of renal
dysfunction in PTA patients despite an adequate eGFR at
the time of transplantation.8
Solitary pancreas grafts are particularly susceptible to
acute rejection, but there are no reliable laboratory or
clinical findings for early detection of these episodes9
except a strict protocol of pancreas biopsies. With accumu-
lated experience in bladder- and enteric-drained pancreas
Fig 1. Overall pancreas graft survival in the cohorts of PTA and
SPK. Three-month, 1-, 3- and 5-year survival rates were 76,6%,
57,4%, 51,1%, and 51.1% in PTA cohort, and 85.7%, 82.1%,
82.1%, and 72.7% in SPK cohort, respectively.transplantation since 2007, we modified our management ofhe pancreas exocrine gland by draining it into the recipient
uodenum.10,11 This technique preffers the advantage of
easy monitoring of the graft by upper endoscopy of the
duodenum. Moreover, duodenal findings on duodenum
biopsies paralleled those of pancreatic tissue biopsies.9,12
Among 7 acute rejection episodes occurring among the
cohort of 10 PTA cases 4 were detected by the surveillance
biopsy. Gruessner et al reported a higher propensity for
native kidney failure among patients who underwent treat-
ment for more than 2 rejection episodes.4
Due to their nephrotoxic side effects CNI remain the
principle culprit for deterioration of renal function. How-
ever, current attempts to avoid CNI altogether have not
been successful.13 Future studies are necessary to deter-
mine whether the incidence of kidney dysfunction can be
reduced by fine-tuning existing PTA protocols.4 The immu-
nological advantage of portal venous drainage with a low
rate of rejection may also permit reduction in immunosup-
pressive therapy with improved long-term outcomes.14,15
Our outcomes of SPK cohort were similar to our previ-
ously reported results16 and comparable to those noted by
ther authors. The PTA cohort, however, displayed a lower
ancreas graft survival than that usually cited in the litera-
ure. Graft losses were mostly due to vascular graft throm-
osis occurring early or late posttransplantation. Explana-
ions for the frequency of thrombosis may include the
ecipient’s vascular status, the pancreas’s low flow rate, and
he vascular reconstruction using an extension graft. Our
bservation has led us to preferentially avoid this recon-
truction, asking the liver procurement team to leave the
Fig 2. Overall patient survival in the cohorts of PTA and SPK.
Three-month, 1-, 3- and 5-year survival rates were 100%, 100%,
93.3% and 93.3% in PTA cohort, and 92.9%, 92.9%, 92.9% and
88.2% in SPK cohort, respectively.
NATIVE KIDNEY FUNCTION 2833pancreatic vessels with the celiac trunk and SMA en bloc on
an aortic patch.16
In conclusion, native kidney function deteriorated signif-
icantly after PTA.
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